Gabriel Leger, MD
Behavioral Neurology & Neuropsychiatry · San Diego, CANPI 1720367899
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,960 of the $4,417 with a category attached, or 89.6%. Eisai Inc. accounts for 91.0% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2022 at $4,020 and has fallen 97.8% since, to $90 in 2025.
Across 14 payments — averaging $315.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$4K
- Genentech, Inc.$190
- Lilly USA, LLC$90
- Biogen$43
- Acorda Therapeutics, Inc$37
- Neurocrine Biosciences, Inc.$21
- plus $16 from 1 others
Across 90 payments — averaging $10,978 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$538K
- AbbVie$405K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$16K
- Avanir Pharmaceuticals, Inc.$12K
- Biohaven Pharmaceutical Holding Company Ltd.$10K
- Biohaven Pharmaceuticals, Inc.$4K
- plus $2K from 2 others
What the payments were for
- Consulting fees$3,96090%
- Speaking & faculty fees$371%
- Travel & lodging$601%
- Food & beverage$1273%
- Education$2335%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 3 | $4,020 |
| Genentech, Inc. | 5 | $190 |
| Lilly USA, LLC | 1 | $90 |
| Biogen | 1 | $43 |
| Acorda Therapeutics, Inc | 2 | $37 |
| Neurocrine Biosciences, Inc. | 1 | $21 |
| Medtronic | 1 | $16 |
How this compares
Too few behavioral neurology & neuropsychiatry providers in Californiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rivastigmine | 19 | $5,897 |
| Donepezil Hcl | 121 | $1,566 |
| Mirtazapine | 47 | $1,096 |
| Galantamine ErGalantamine Hbr | 15 | $1,054 |
| Sertraline Hcl | 64 | $1,004 |
| Memantine Hcl | 31 | $694 |
| Memantine Hcl ErMemantine Hcl | 18 | $640 |
| Trazodone Hcl | 14 | $507 |
| Quetiapine Fumarate | 11 | $164 |
| Escitalopram Oxalate | 13 | $68 |
Paid to pharmacies, not to this prescriber.
Other behavioral neurology & neuropsychiatry in San Diego
- Collins LiuSan Diego$37K
- Anish DhamijaSan Diego$57
- Nihal DesilvaSan Diego$32
- Seyed SajjadiOrange$10K
- Neda HeidariOxnard$8K
- Sharon ShaStanford$8K
- Michael FrazierWestminster$8K
- Paramjit SinghChico$4K
- Peter WagnerRancho Mirage$666
- Balasubramaniam GulasekaramCerritos$310
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.